Overview

Safety and Efficacy Study of Glufosfamide in Ovarian Cancer

Status:
Terminated
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Primary Objectives: - To evaluate the effect of glufosfamide on the serum concentrations of CA125 in subjects with ovarian cancer - To evaluate the safety of weekly glufosfamide dosing in subjects with ovarian cancer as compared with every 21-day dosing Secondary objectives: - To evaluate the efficacy of glufosfamide in subjects with ovarian cancer as measured by objective response rate, duration of response, progression-free survival, and overall survival - To evaluate the pharmacokinetics of glufosfamide and isophosphoramide mustard during and after treatment Exploratory objective: - To correlate efficacy endpoints with expression of tumor-associated glucose transporter proteins
Phase:
Phase 2
Details
Lead Sponsor:
Eleison Pharmaceuticals LLC.
Treatments:
Ifosfamide